Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7622153 | 0.79 | SORD (0.32) | — | |
| SCHEMBL4388950 | 0.76 | — | — | |
| SCHEMBL4386625 | 0.75 | — | — | |
| SCHEMBL8172829 | 0.74 | — | — | |
| SCHEMBL8173247 | 0.73 | — | — | |
| SCHEMBL6956560 | 0.73 | — | — | |
| SCHEMBL6956651 | 0.73 | — | — | |
| SCHEMBL8166042 | 0.73 | — | — | |
| SCHEMBL3749348 | 0.72 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL4056925 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370533-B1 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-6841684-B2 | For therapy of chronic pain, glaucoma or elevated intraocular pressure and other diseases with substantially reduced cardiovascular or sedative side effects | ALLERGAN, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1036065-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1413576-A2 | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors | Allergan, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ALLERGAN SALES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ALLERGAN SALES, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6329369-B1 | ANALGESICS FOR TREATING GLAUCOMA OR ELEVATED PRESSURE AND OTHER DISEASES WITH REDUCED SIDE EFFECTS BY TREATING A MAMMAL IN NEED THEREOF AN AGONIST OF ALPHA 2B OR ALPHA 2B/2C ADRENERGIC RECEPTOR | ALLERGAN SALES, INC. | 2001-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ADRA2B, ADRB2, ADRA2C | ALDH1A1 769/4885CTSS 3605/4885 |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ADRB2, ADRB1, ADRA2B | ALDH1A1 1129/4885CTSS 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.